Development of broadly neutralizing nanobodies for advancing aids therapy

Ended Grant Awarded Last action

Award ID
R01AI186812
Recipient
Awarding agency
Obligated
$2,414,136

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Place of performance
Atlanta, GA 30303, USA

Award details come from USAspending.gov.

Description

Abstract
Human immunodeficiency virus (HIV) remains a persistent global health crisis, affecting approximately 39 million individuals worldwide, despite considerable advancements in prevention and treatment. While strides have been made with antiretroviral therapies (art) and other interventions, managing HIV continues to pose significant challenges. Broadly neutralizing antibodies (BNABS) have emerged as promising tools against HIV-1. However, their widespread use faces hurdles such as resistance development and complex administration. Consequently, exploring alternative strategies, notably nanobodies, gains prominence in HIV research. Nanobodies, recognized for their compact structure, effective tissue penetration, and unique epitope recognition, offer a novel avenue for combatting HIV. This study concentrates on harnessing diverse nanobody development strategies to identify and engineer these smaller antibodies, with a specific focus on targeting multiple sites on the HIV virus ENV protein. The primary goal is to bolster treatment effectiveness while simplifying therapeutic protocols. Empirical evidence suggests that engineered antibodies, simultaneously targeting diverse sites on the HIV ENV, may outperform traditional BNABS in efficacy against a range of HIV strains. Our proposal outlines three primary objectives: first, identifying versatile nanobodies capable of recognizing various regions of the HIV ENV through advanced phage-display screening; second, conducting comprehensive characterization, including neutralization studies, bioinformatic, and structural analyses, to deepen our understanding of these nanobodies' mechanisms; and finally, enhancing their efficacy by leveraging structural insights for rational design to broaden their targeting capabilities. This thorough exploration into nanobody-based therapies holds significant potential to revolutionize HIV treatment strategies. By potentially overcoming existing limitations and offering innovative pathways in HIV management, these advancements could substantially impact the ongoing battle against this persistent viral challenge.

Transactions

Action Obligated Date
Amendment $0
Amendment $847,478
Amendment $0
Amendment $776,329
Amendment $79,033
Original award $711,296

Subawards

Subrecipient Amount Awarded
The Ohio State University Scope of Work (SOW) A. Title Development of Broadly Neutralizing Nanobodies for Advancing AIDS Therapy B. Project Background HIV presents a multifaceted… $382,741
The Ohio State University Scope of Work (SOW) A. Title Development of Broadly Neutralizing Nanobodies for Advancing AIDS Therapy B. Project Background HIV presents a multifaceted… $382,741

Quick answers

Who received award R01AI186812?

R01AI186812 was awarded to Georgia State University Research Foundation Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2024.

How much is award R01AI186812 worth?

$2,414,136 has been obligated on R01AI186812.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award